Health
Ascletis' Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted Weight Loss of 7.7% with Better Gastrointestinal Tolerability in Its 13-Week U.S. Phase II Study in Participants with Obesity or Overweight
Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today positive topline results in its 13-week Phase II study evaluating ASC30, an oral small molecule GLP-1 receptor (GLP-1R) agonist for the treatment of obesity (NCT07002905) in 125 participants with obesity or overweight with at least one weight-related comorbidity at multiple sites across the U.S. Three dose levels of ASC30 oral tablets were investigated (20 mg, 40 mg and 60 mg). At 13 weeks, all three doses of ASC30 met the primary end
About this update from Ascletis Pharma, Inc.
[{"type":"text","content":"- ASC30 once-daily tablets showed statistically significant and clinically meaningful dose-dependent placebo-adjusted mean body weight reductions with no observed plateau for weight loss. ","length":187,"tagName":"p"},{"type":"text","content":"- ASC30 titrated weekly to target dose demonstrated approximately one-half the rate of vomiting observed with orforglipron titrated weekly. ","length":139,"tagName":"p"},{"type":"text","content":"- No hepatic safety signal was observed, and no elevations of alanine transaminase (ALT), aspartate aminotransferase (AST) or total bilirubin (TBL) were observed.","length":162,"tagName":"p"},{"type":"text","content":"- Two conference calls/webcasts are scheduled to discuss the results, including a Mandarin session at 8:00 p.m. China Standard Time today, December 8, 2025, and an English session at 10:00 a.m. Eastern Standard Time today, December 8, 2025.","length":240,"tagName":"p"},{"type":"text","content":"HONG KONG, Dec. 8, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today positive topline results in its 13-week Phase II study evaluating ASC30, an oral small molecule GLP-1 receptor (GLP-1R) agonist for the treatment of obesity (NCT07002905) in 125 participants with obesity or overweight with at least one weight-related comorbidity at multiple sites across the U.S. Three dose levels of ASC30 oral tablets were investigated (20 mg, 40 mg and 60 mg). At 13 weeks, all three doses of ASC30 met the primary endpoint compared to placebo, demonstrating statistically significant (p values < 0.0001 for 20 mg, 40 mg and 60 mg vs placebo) and clinically meaningful weight loss. On the primary endpoint of mean percent change in body weight from baseline at 13 weeks, 60 mg ASC30 delivered a placebo-adjusted mean weight loss of 7.7%.","length":872,"tagName":"p"},{"type":"text","content":"At the 13-week primary endpoint, ASC30 once-daily tablets showed dose-dependent placebo-adjusted mean body weight reductions of 5.4%, 7.0% and 7.7% for 20 mg, 40 mg and 60 mg, respectively. No plateau was observed for weight loss. The baseline mean body weight and body mass index (BMI) of participants were 107.3 kg and 38.6 kg/m2, respectively.","length":366,"tagName":"p"},{"type":"text","content":"80.0% of participants taking 60 mg of ASC30 once daily lost ≥5% of...